DE112005001260A5 - Antigen des PM-2 Antikörpers und dessen Verwendung - Google Patents

Antigen des PM-2 Antikörpers und dessen Verwendung Download PDF

Info

Publication number
DE112005001260A5
DE112005001260A5 DE112005001260T DE112005001260T DE112005001260A5 DE 112005001260 A5 DE112005001260 A5 DE 112005001260A5 DE 112005001260 T DE112005001260 T DE 112005001260T DE 112005001260 T DE112005001260 T DE 112005001260T DE 112005001260 A5 DE112005001260 A5 DE 112005001260A5
Authority
DE
Germany
Prior art keywords
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE112005001260T
Other languages
English (en)
Inventor
Heinz Vollmers
Frank Hensel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncomab GmbH
Original Assignee
Oncomab GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomab GmbH filed Critical Oncomab GmbH
Publication of DE112005001260A5 publication Critical patent/DE112005001260A5/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
DE112005001260T 2004-03-25 2005-03-10 Antigen des PM-2 Antikörpers und dessen Verwendung Withdrawn DE112005001260A5 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102004015179.2 2004-03-25
DE102004015179A DE102004015179A1 (de) 2004-03-25 2004-03-25 Antigen des PM-2 Antikörpers und dessen Verwendung
DE112005001260 2005-03-10
PCT/DE2005/000455 WO2005092922A2 (de) 2004-03-25 2005-03-10 Antigen des pm-2 antikörpers und dessen verwendung

Publications (1)

Publication Number Publication Date
DE112005001260A5 true DE112005001260A5 (de) 2007-05-31

Family

ID=34983001

Family Applications (2)

Application Number Title Priority Date Filing Date
DE102004015179A Withdrawn DE102004015179A1 (de) 2004-03-25 2004-03-25 Antigen des PM-2 Antikörpers und dessen Verwendung
DE112005001260T Withdrawn DE112005001260A5 (de) 2004-03-25 2005-03-10 Antigen des PM-2 Antikörpers und dessen Verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE102004015179A Withdrawn DE102004015179A1 (de) 2004-03-25 2004-03-25 Antigen des PM-2 Antikörpers und dessen Verwendung

Country Status (5)

Country Link
US (1) US20080281083A1 (de)
EP (1) EP1727832A2 (de)
JP (1) JP2008502321A (de)
DE (2) DE102004015179A1 (de)
WO (1) WO2005092922A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003249533A1 (en) * 2002-07-04 2004-01-23 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP2234640A1 (de) * 2007-12-21 2010-10-06 Patrys Limited Pm-2-antikörper und verfahren zur behandlung von metastasen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
DE4107154A1 (de) * 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
US5639863A (en) * 1994-06-21 1997-06-17 Dan; Michael D. Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
GB9822115D0 (en) * 1998-10-09 1998-12-02 King S College London Treatment of inflammatory disease
US7049132B1 (en) * 1999-06-28 2006-05-23 University Of Southern California Stress-responsive induction of a therapeutic agent and methods of use
US6677442B1 (en) * 1999-10-29 2004-01-13 University Of Kentucky Research Foundation Nucleic acid encoding human REV1 protein
JP4344237B2 (ja) * 2001-07-24 2009-10-14 デビオビジョン・インコーポレーテッド 受容体、その使用、およびそのマウス抗体
DE10230516A1 (de) * 2002-07-06 2004-01-15 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
US20050123571A1 (en) * 2003-06-06 2005-06-09 Rossini Aldo A. Modulation of apoptosis

Also Published As

Publication number Publication date
WO2005092922A3 (de) 2006-07-27
EP1727832A2 (de) 2006-12-06
US20080281083A1 (en) 2008-11-13
WO2005092922A2 (de) 2005-10-06
DE102004015179A1 (de) 2005-10-13
JP2008502321A (ja) 2008-01-31

Similar Documents

Publication Publication Date Title
CY2016035I2 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
DE60229509D1 (de) Anti-osteopontin-antikörper und dessen verwendung
SG10201606980VA (en) Anti-cd3 antibodies and methods of use thereof
IL190502A0 (en) Anti-addl monoclonal antibody and use thereof
IL178593A (en) Specific antibodies of fcγriib and methods for their use
EP1717250A4 (de) Monoklonaler antikörper und dessen verwendung
EP1940466A4 (de) Monoklonaler antikörper gegen addl und anwendung davon
NO20080692L (no) SP35 antistoffer og anvendelse derav
EP1787998A4 (de) Antikörper und deren verwendung
DK1599504T3 (da) Modificeret antistof
DE602005003186D1 (de) Fluorkopolymer und dessen Verwendung
DE602005022169D1 (de) Polymerisierbare verbindungen und verwendung davon
ATE535545T1 (de) Chimäre und humanisierte monoklonale antikörper gegen interleukin-13
IL176755A0 (en) M-csf-specific monoclonal antibody and uses thereof
DE602004026768D1 (de) Therapeutische anti-igfr1-antikörper-kombinationen
IL192129A0 (en) Anti-mn antibodies and methods of using same
CY2013046I2 (el) Καινοτομος χρηση των αντισωματων αντι il-1bhta
EP1840135A4 (de) Gegen alpha 9-integrin gerichteter antikörper und anwendung davon
EP1789027A4 (de) Therapeutische verwendung von anti-tf-antigen-antikörper
EP2048162A4 (de) Neuer monoklonaler antikörper und seine verwendung
DE112005001260A5 (de) Antigen des PM-2 Antikörpers und dessen Verwendung
ITRM20050478A1 (it) Apparato per l'applicazione contemporanea della carbossiterapia e della mesoterapia.
EP1919951A4 (de) Anti-tnf-alpha-antikörper und anwendungsverfahren
EP1633850A4 (de) Ovr115-antikörperzusammensetzung und verwendungsverfahren
ATE518887T1 (de) Anti-igsf4-antikörper und dessen verwendung

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee